Parabilis Medicines, Inc.

PBLSReported to SECin USCIK 0001657677Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 7
Form 4 lines at Parabilis Medicines, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Tendler Craig—Awardnothing paid20,294 sharesAug 25, 2026Tendler Craignothing paidAward · Aug 25Award20,294Aug 25, 2026
RA CAPITAL MANAGEMENT, L.P.—Open-market buy$1,406,63347,250 sharesJul 22, 2026RA CAPITAL MANAGEMENT, L.P.$1,406,633Buy · Jul 22Open-market buy47,250Jul 22, 2026
RA CAPITAL MANAGEMENT, L.P.—Open-market buy$1,131,69037,723 sharesJul 22, 2026RA CAPITAL MANAGEMENT, L.P.$1,131,690Buy · Jul 22Open-market buy37,723Jul 22, 2026
RA CAPITAL MANAGEMENT, L.P.—Open-market buy$189,7226,504 sharesJul 22, 2026RA CAPITAL MANAGEMENT, L.P.$189,722Buy · Jul 22Open-market buy6,504Jul 22, 2026
RA CAPITAL MANAGEMENT, L.P.—Open-market buy$606,62021,696 sharesJul 22, 2026RA CAPITAL MANAGEMENT, L.P.$606,620Buy · Jul 22Open-market buy21,696Jul 22, 2026